Association between estrogen and androgen receptor genes and prostate cancer risk

European Journal of Endocrinology

Volumn 160, Issue 1, 2009, Pages 101-106

  Nicolaiew, Nathalie ^b   Cancel Tassin, Geraldine ^a   Azzouzi, Abdel Rahmene ^a,d   Le Grand, Beatrice ^e   Mangin, Philippe ^a,f   Cormier, Luc ^a,f   Fournier, Georges ^a,g   Giordanella, Jean Pierre ^h   Pouchard, Michel ^h   Escary, Jean Louis ⁱ   Valeri, Antoine ^a,g   Cussenot, Olivier ^a,c  

^a HÔPITAL TENON   (France)

^b FACULTÉ DE MÉDECINE   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f CHU NANCY BRABOIS   (France)

^g SERVICE DE RHUMATOLOGIE   (France)

^h Bioinformatique et Chimie Moléculaire   (France)

ⁱ NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ALPHA ESTROGEN RECEPTOR 1; ANDROGEN RECEPTOR; BETA ESTROGEN RECEPTOR 2; ESTROGEN RECEPTOR; GUANINE; PURINE; UNCLASSIFIED DRUG; DNA; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MICROSATELLITE DNA;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CANCER RISK; CAUCASIAN; CONTROLLED STUDY; DNA POLYMORPHISM; GENE FREQUENCY; GENE LOCATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLEASON SCORE; HORMONE ACTION; HUMAN; INTRON; MAJOR CLINICAL STUDY; NUCLEOTIDE REPEAT; POPULATION RISK; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; RISK ASSESSMENT; ADENOCARCINOMA; CASE CONTROL STUDY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MALE; METABOLISM; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROSTATE TUMOR;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DNA, NEOPLASM; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 58249092971     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-08-0321     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C & Thun MJ. Cancer statistics. CA: A Cancer Journal for Clinicians 2006 56 106-130.
2. De Marzo AM, Nelson WG, Meeker AK & Coffey DS. Stem cell features of benign and malignant prostate epithelial cells. Journal of Urology 1998 160 2381-2392.
3. Harkonen PL & Makela SI. Role of estrogens in development of prostate cancer. Journal of Steroid Biochemistry and Molecular Biology 2004 92 297-305.
4. Ruizeveld De Winter JA, Janssen PJ, Sleddens HM, Verleun-Mooijman MC, Trapman J, Brinkmann AO, Santerse AB, Schroder FH & Van Der Kwast TH. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. American Journal of Pathology 1994 144 735-746.
5. Bonkhoff H, Fixemer T, Hunsicker I & Remberger K. Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. American Journal of Pathology 1999 155 641-647.
6. Horvath LG, Henshall SM, Lee CS, Head DR, Quinn DI, Makela S, Delprado W, Golovsky D, Brenner PC, O'Neill G, Kooner R, Stricker PD, Grygiel JJ, Gustafsson JA & Sutherland RL. Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Research 2001 61 5331-5335.
7. Latil A, Bieche I, Vidaud D, Lidereau R, Berthon P, Cussenot O & Vidaud M. Evaluation of androgen, estrogen (ER α and ER β), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Research 2001 61 1919-1926.
8. Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME,Wang J, Singh H & Ho SM. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. American Journal of Pathology 2001 159 79-92.
9. Santti R, Newbold RR, Makela S, Pylkkanen L & McLachlan JA. Developmental estrogenization and prostatic neoplasia. Prostate 1994 24 67-78.
10. Prins GS, Birch L, Couse JF, Choi I, Katzenellenbogen B & Korach KS. Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: studies with alphaERKO and betaERKO mice. Cancer Research 2001 61 6089-6097.
11. Weihua Z, Lathe R, Warner M & Gustafsson JA. An endocrine pathway in the prostate, ERβ, AR, 5α-androstane-3β,17β-diol, and CYP7B1, regulates prostate growth. PNAS 2002 99 13589-13594.
12. Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P & Mark M. Effect of single and compound knockouts of estrogen receptors alpha (ERα) and beta (ERβ) on mouse reproductive phenotypes. Development 2000 127 4277-4291.
13. Cavalieri EL, Devanesan P, Bosland MC, Badawi AF & Rogan EG. Catechol estrogen metabolites and conjugates in different regions of the prostate of Noble rats treated with 4-hydroxyestradiol: implications for estrogen-induced initiation of prostate cancer. Carcinogenesis 2002 23 329-333.
14. Bosland MC, Ford H & Horton L. Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17 beta or diethylstilbestrol. Carcinogenesis 1995 16 1311-1317.
15. Cancel-Tassin G, Latil A, Rousseau F, Mangin P, Bottius E, Escary JL, Berthon P & Cussenot O. Association study of polymorphisms in the human estrogen receptor alpha gene and prostate cancer risk. European Urology 2003 44 487-490.
16. Hakimi JM, Schoenberg MP, Rondinelli RH, Piantadosi S & Barrack ER. Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. Clinical Cancer Research 1997 3 1599-1608.
17. Latil AG, Azzouzi R, Cancel GS, Guillaume EC, Cochan-Priollet B, Berthon PL & Cussenot O. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 2001 92 1130-1137.
18. Thellenberg-Karlsson C, Lindstrom S, Malmer B, Wiklund F, Augustsson-Balter K, Adami HO, Stattin P, Nilsson M, Dahlman-Wright K, Gustafsson JA & Gronberg H. Estrogen receptor beta polymorphism is associated with prostate cancer risk. Clinical Cancer Research 2006 12 1936-1941.
19. Freedman ML, Pearce CL, Penney KL, Hirschhorn JN, Kolonel LN, Henderson BE & Altshuler D. Systematic evaluation of genetic variation at the androgen receptor locus and risk of prostate cancer in a multiethnic cohort study. American Journal of Human Genetics 2005 76 82-90.
20. Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen YC, Stampfer MJ, Willett WC & Giovannucci E. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiology, Biomarkers and Prevention 2005 14 1262-1269.
21. Simard J, Dumont M, Labuda D, Sinnett D, Meloche C, El-Alfy M, Berger L, Lees E, Labrie F & Tavtigian SV. Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocrine-Related Cancer 2003 10 225-259.
22. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, Talcott J, Hennekens CH & Kantoff PW. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. PNAS 1997 94 3320-3323.
23. Andersson P, Varenhorst E & Soderkvist P. Androgen receptor and vitamin D receptor gene polymorphisms and prostate cancer risk. European Journal of Cancer 2006 42 2833-2837.
24. Lindstrom S, Zheng SL, Wiklund F, Jonsson BA, Adami HO, Balter KA, Brookes AJ, Sun J, Chang BL, Liu W, Li G, Isaacs WB, Adolfsson J, Gronberg H & Xu J. Systematic replication study of reported genetic associations in prostate cancer: strong support for genetic variation in the androgen pathway. Prostate 2006 66 1729-1743.
25. Forrest MS, Edwards SM, Houlston R, Kote-Jarai Z, Key T, Allen N, Knowles MA, Turner F, Ardern-Jones A, Murkin A, Williams S, Oram R, Bishop DT & Eeles RA. Association between hormonal genetic polymorphisms and early-onset prostate cancer. Prostate Cancer and Prostatic Diseases 2005 8 95-102.
26. Zeegers MP, Kiemeney LA, Nieder AM & Ostrer H. How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk? Cancer Epidemiology, Biomarkers and Prevention 2004 13 1765-1771.
27. Hardy DO, Scher HI, Bogenreider T, Sabbatini P, Zhang ZF, Nanus DM & Catterall JF. Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. Journal of Clinical Endocrinology and Metabolism 1996 81 4400-4405.
28. Modugno F, Weissfeld JL, Trump DL, Zmuda JM, Shea P, Cauley JA & Ferrell RE. Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clinical Cancer Research 2001 7 3092-3096.
29. Berndt SI, Chatterjee N, Huang WY, Chanock SJ, Welch R, Crawford ED & Hayes RB. Variant in sex hormone-binding globulin gene and the risk of prostate cancer. Cancer Epidemiology, Biomarkers and Prevention 2007 16 165-168.
30. Hernandez J, Balic I, Johnson-Pais TL, Higgins BA, Torkko KC, Thompson IM & Leach RJ. Association between an estrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men. Journal of Urology 2006 175 523-527.